PRESS RELEASE published on 06/09/2026 at 07:45, 4 months 29 days ago EQS-Adhoc: Pentixapharm Holding AG: FDA grants “Study May Proceed” for Phase 3 Study; Intended Capital Increase with Subscription Rights of up to 10 Million Shares; BaFin Financial Reporting Enforcement Review Pentixapharm Holding AG receives FDA clearance for Phase 3 study, plans capital increase of up to 10 million shares with subscription rights, and faces BaFin financial review FDA Clearance Capital Increase Phase 3 Study Pentixapharm Holding AG BaFin Review
BRIEF published on 05/11/2026 at 08:05, 5 months 28 days ago Pentixapharm Submits IND to FDA for Phase 3 PANDA Study Pentixapharm Precision Diagnostics FDA IND Submission Phase 3 PANDA Cardiovascular Imaging
BRIEF published on 05/11/2026 at 08:05, 5 months 28 days ago Pentixapharm soumet une demande d'autorisation d'essai clinique (IND) à la FDA pour l'étude de phase 3 PANDA. Diagnostic De Précision Pentixapharm Phase 3 PANDA Soumission D'autorisation De Mise Sur Le Marché (IND) À La FDA Imagerie Cardiovasculaire
PRESS RELEASE published on 05/11/2026 at 08:00, 5 months 28 days ago Pentixapharm Announces IND Submission to FDA for Phase 3 PANDA Study of First-in-Class CXCR4-Targeted Cardiovascular Diagnostic Pentixapharm submits IND to FDA for Phase 3 PANDA study of CXCR4-targeted cardiovascular diagnostic, aiming at precision diagnostics in primary aldosteronism Pentixapharm IND Submission Phase 3 PANDA Study CXCR4-targeted Cardiovascular Diagnostic
BRIEF published on 05/07/2026 at 08:05, 6 months 1 day ago Pentixapharm Q1 2026 Financial and Clinical Development Update Financial Results Clinical Development Radiopharmaceuticals Cost Management Regulatory Feedback
BRIEF published on 05/07/2026 at 08:05, 6 months 1 day ago Point sur le développement financier et clinique de Pentixapharm au premier trimestre 2026 Résultats Financiers Développement Clinique Gestion Des Coûts Produits Radiopharmaceutiques Commentaires Réglementaires
PRESS RELEASE published on 05/07/2026 at 08:00, 6 months 1 day ago Pentixapharm Reports First Quarter 2026 Results and Highlights Clinical and Regulatory Momentum Pentixapharm Holding AG reports Q1 2026 financial results, highlights progress in clinical and regulatory activities, and provides full-year financial guidance Financial Results Regulatory Pentixapharm Q1 2026 Clinical
BRIEF published on 03/31/2026 at 08:05, 7 months 8 days ago Pentixapharm Holding AG Appoints Erik Merten to Executive Board Executive Board Radiopharmaceuticals Pentixapharm Erik Merten PANDA Program
BRIEF published on 03/31/2026 at 08:05, 7 months 8 days ago Pentixapharm Holding AG nomme Erik Merten au conseil d'administration Conseil D'administration Produits Radiopharmaceutiques Pentixapharm Erik Merten Programme PANDA
PRESS RELEASE published on 03/31/2026 at 08:00, 7 months 8 days ago Pentixapharm Holding AG Appoints Erik Merten to the Executive Board Pentixapharm Holding AG appoints Erik Merten as Chief Technology Officer (CTO) to enhance radiopharmaceutical development and manufacturing capabilities, supporting Phase 3 PANDA program and future commercialization Executive Board Radiopharmaceuticals Pentixapharm Holding AG Erik Merten Phase 3 PANDA Program
Published on 11/06/2026 at 22:15, 1 day 15 hours ago Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders
Published on 11/06/2026 at 13:00, 2 days ago Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 2 days 1 hour ago Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 2 days 1 hour ago Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/08/2026 at 12:10, 1 hour 39 minutes ago GSMA MWC26 Doha opens with call to align on global industry standards and close MENA's connectivity gap
Published on 11/08/2026 at 10:15, 3 hours 34 minutes ago 2026 China International Intelligent Communication Forum Held in Wuxi
Published on 11/07/2026 at 13:35, 1 day ago Eurobattery Minerals board member and CEO remanded in custody in Sweden
Published on 11/06/2026 at 20:15, 1 day 17 hours ago African Medicines Agency Marks First Year of Operations with New Platforms to Strengthen Regulation and Support Manufacturing
Published on 11/06/2026 at 20:15, 1 day 17 hours ago L’Agence africaine des médicaments marque sa première année d’activité avec le lancement de nouvelles plateformes pour renforcer la réglementation et soutenir la fabrication
Published on 11/06/2026 at 19:06, 1 day 18 hours ago ALTAREIT : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES OCTOBRE 2026
Published on 11/06/2026 at 19:04, 1 day 18 hours ago ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 11/06/2026 at 19:01, 1 day 18 hours ago ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES OCTOBRE 2026
Published on 11/06/2026 at 19:00, 1 day 18 hours ago ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
